{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:38Z","timestamp":1786980518839,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T00:00:00Z","timestamp":1322524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10067-011-1887-y","type":"journal-article","created":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T13:34:07Z","timestamp":1322487247000},"page":"717-722","source":"Crossref","is-referenced-by-count":35,"title":["The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis"],"prefix":"10.1007","volume":"31","author":[{"given":"Richard Charles John","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Batley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fowzia","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,29]]},"reference":[{"key":"1887_CR1","first-page":"1407","volume":"23","author":"F Wolfe","year":"1996","unstructured":"Wolfe F, Hawley DJ, Wilson K (1996) The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 23:1407","journal-title":"J Rheumatol"},{"key":"1887_CR2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","volume":"24","author":"RS Pinals","year":"1981","unstructured":"Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308","journal-title":"Arthritis Rheum"},{"key":"1887_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00006199-199303000-00006","volume":"42","author":"BL Belza","year":"1993","unstructured":"Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL (1993) Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 42:93","journal-title":"Nurs Res"},{"key":"1887_CR4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/rheumatology\/keg281","volume":"42","author":"P Minnock","year":"2003","unstructured":"Minnock P, FitzGerald O, Bresnihan B (2003) Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology (Oxford) 42:995","journal-title":"Rheumatology (Oxford)"},{"key":"1887_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS19990372","volume":"99","author":"MG Swain","year":"2000","unstructured":"Swain MG (2000) Fatigue in chronic disease. Clin Sci 99:1","journal-title":"Clin Sci"},{"key":"1887_CR6","first-page":"1171","volume":"34","author":"JR Kirwan","year":"2007","unstructured":"Kirwan JR, Hewlett S (2007) Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 34:1171","journal-title":"J Rheumatol"},{"key":"1887_CR7","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober (2005) Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811","journal-title":"J Rheumatol"},{"key":"1887_CR8","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563","journal-title":"J Rheumatol"},{"key":"1887_CR9","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multi-center, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793","journal-title":"Arthritis Rheum"},{"key":"1887_CR10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, OPTION Investigators (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987","journal-title":"Lancet"},{"key":"1887_CR11","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400","journal-title":"Arthritis Rheum"},{"key":"1887_CR12","first-page":"20","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M (2008) Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol 35:20","journal-title":"J Rheumatol"},{"key":"1887_CR13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35","journal-title":"Arthritis Rheum"},{"key":"1887_CR14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390","journal-title":"Arthritis Rheum"},{"key":"1887_CR15","first-page":"2343","volume":"34","author":"T Mittendorf","year":"2007","unstructured":"Mittendorf T, Dietz B, Sterz R, Kupper H, Cifaldi MA, von der Schulenburg JM (2007) Improvement and long term maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol 34:2343","journal-title":"J Rheumatol"},{"key":"1887_CR16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114","journal-title":"N Engl J Med"},{"key":"1887_CR17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2006.057018","volume":"66","author":"AS Russell","year":"2007","unstructured":"Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P (2007) Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 66:189","journal-title":"Ann Rheum Dis"},{"key":"1887_CR18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/kel066","volume":"45","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y (2006) Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multi-centre randomized clinical trial. Rheumatology 45:1238","journal-title":"Rheumatology"},{"key":"1887_CR19","first-page":"838","volume":"25","author":"S Yount","year":"2007","unstructured":"Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK (2007) Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 25:838\u2013846","journal-title":"Clin Exp Rheumatol"},{"key":"1887_CR20","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/1529-0131(199812)41:12<2230::AID-ART19>3.0.CO;2-D","volume":"41","author":"BA Huyser","year":"1998","unstructured":"Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R (1998) Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 41:2230","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1887_CR21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/rheumatology\/kel021","volume":"45","author":"LC Pollard","year":"2006","unstructured":"Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL (2006) Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 45(7):885","journal-title":"Rheumatology"},{"key":"1887_CR22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/berh.1999.0046","volume":"13","author":"PG Conaghan","year":"1999","unstructured":"Conaghan PG, Green MJ, Emery P (1999) Established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 13:561\u2013575","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"1887_CR23","first-page":"2115","volume":"31","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K (2004) Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 31:2115","journal-title":"J Rheumatol"},{"key":"1887_CR24","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381","journal-title":"Arthritis Rheum"},{"key":"1887_CR25","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/keq210","volume":"49","author":"S Nikolaus","year":"2010","unstructured":"Nikolaus S, Bode C, Taal E, Van de Laar M (2010) Four different patterns of fatigue in rheumatoid arthritis patients: results of a Q-sort study. Rheumatology 49:2191\u20132199","journal-title":"Rheumatology"},{"key":"1887_CR26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/rheumatology\/kem109","volume":"46","author":"MC Greenwood","year":"2007","unstructured":"Greenwood MC, Rathi J, Hakim AJ, Scott DL, Doyle DV (2007) Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis. Rheumatology 46:1165\u20131167","journal-title":"Rheumatology"},{"issue":"9","key":"1887_CR27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00520-010-0971-1","volume":"19","author":"D Cella","year":"2011","unstructured":"Cella D, Lai JS, Stone A (2011) Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy\u2014Fatigue (FACIT-F) questionnaire. Support Care Cancer 19(9):1441\u20131450","journal-title":"Support Care Cancer"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-011-1887-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1887-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:51:53Z","timestamp":1559105513000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-011-1887-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,29]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1887"],"URL":"https:\/\/doi.org\/10.1007\/s10067-011-1887-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,29]]}}}